BPC
TEVA icon

Banque Pictet & Cie’s Teva Pharmaceuticals TEVA Stock Holding History

Banque Pictet & Cie’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-33,864
Closed -$300K – 596
2023
Q1 		$300K Sell
33,864
-45,825
-58% -$453K ﹤0.01% 531
2022
Q4 		$727K Sell
79,689
-847,729
-91% -$7.4M 0.01% 443
2022
Q3 		$7.48M Sell
927,418
-3,814
-0.4% -$33.7K 0.08% 122
2022
Q2 		$7K Sell
931,232
-44,578
-5% -$388K 0.07% 135
2022
Q1 		$9.16M Buy
975,810
+2,682
+0.3% +$22.4K 0.07% 128
2021
Q4 		$7.79M Sell
973,128
-9,723
-1% -$87.8K 0.06% 164
2021
Q3 		$9.57M Sell
982,851
-4,311
-0.4% -$40.4K 0.1% 92
2021
Q2 		$9.83M Sell
987,162
-8,042
-0.8% -$85.1K 0.11% 93
2021
Q1 		$11.3M Buy
995,204
+895,741
+901% +$10.3M 0.15% 87
2020
Q4 		$946K Buy
99,463
+39,768
+67% +$381K 0.01% 236
2020
Q3 		$541K Sell
59,695
-6,750
-10% -$71.4K 0.01% 250
2020
Q2 		$800K Hold
66,445
– – 0.01% 235
2020
Q1 		$612K Buy
+66,445
New +$681K 0.01% 246
2019
Q2 		– Sell
-60,994
Closed -$950K – 338
2019
Q1 		$950K Sell
60,994
-2,651
-4% -$46.8K 0.02% 218
2018
Q4 		$999K Sell
63,645
-47,532
-43% -$974K 0.02% 214
2018
Q3 		$2.44M Buy
111,177
+4,049
+4% +$94K 0.05% 177
2018
Q2 		$2.54M Buy
107,128
+12,338
+13% +$252K 0.05% 178
2018
Q1 		$1.61M Buy
+94,790
New +$1.85M 0.03% 224
2017
Q4 		– Sell
-106,449
Closed -$1.86M – 364
2017
Q3 		$1.86M Buy
106,449
+41,504
+64% +$934K 0.04% 211
2017
Q2 		$2.15M Sell
64,945
-407,438
-86% -$12.6M 0.05% 205
2017
Q1 		$15.5M Buy
+472,383
New +$16.1M 0.38% 53

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Banque Pictet & Cie's TEVA Position: Q2 2023 in Review

Banque Pictet & Cie sold out of Teva Pharmaceuticals (TEVA) in Q2 2023, closing a stake of 33,864 shares — an estimated $300K sold.

Banque Pictet & Cie first reported a position in TEVA in Q1 2017 and held it in 21 quarters. The position peaked at $15.5M in Q1 2017. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

  • Banque Pictet & Cie reported no remaining Teva Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Banque Pictet & Cie sold 33,864 Teva Pharmaceuticals shares in Q2 2023, an estimated $300K.
  • Banque Pictet & Cie first reported a position in Teva Pharmaceuticals in Q1 2017 and held it in 21 quarters.
  • Banque Pictet & Cie's Teva Pharmaceuticals position peaked at $15.5M in Q1 2017.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on Banque Pictet & Cie's 13F filing for Q2 2023, filed 4 Aug 2023.